Glioblastomas are the most aggressive of the brain tumors occurring in adults and children. Currently available chemotherapy prolongs the median survival time of patients by only 4 months. The low efficiency of current treatments is partly owing to the blood-brain barrier, which restricts the penetration of most drugs into the central nervous system. Locoregional treatment strategies thus become mandatory. In this context, viral tools are of great interest for the selective delivery of genes into tumoral cells. Gliomas express high levels of type 2 somatostatin receptors (sstr2A), pinpointing them as suitable targets for the improvement of transduction efficiency in these tumors. We designed a new adenoviral vector based on the introduction of the full-length somatostatin (SRIF (somatotropin release-inhibiting factor)) sequence into the HI loop of the HAdV fiber protein.
INTRODUCTION
Anaplastic gliomas (grade III) and glioblastomas (grade IV) are the most aggressive brain tumors in adults, with a median survival time of patients of 24 and 9 months, respectively.
1 Their aggressiveness is due to their rapid proliferation, high angiogenic levels and their ability to infiltrate the surrounding healthy tissue. Surgery, external beam radiation therapy and systemic chemotherapy do not greatly prolong the median survival time (1-2 years at best). The long-term side effects of central nervous system (CNS) tumors, owing to the location of the primary lesions and the aggressive therapy received by patients, account for their high rates of morbidity. The poor efficacy of the systemic chemotherapy currently available for brain tumor treatment is partly due to the presence of the blood-brain barrier, which separates the blood from the cerebral parenchyma and restricts the penetration of most drugs into the CNS. Because of the poor prognosis of malignant CNS tumors, new locoregional treatment modalities are being developed, and gene therapy approaches have received widespread attention for the treatment of gliomas. 2 Various viral vectors are available for CNS targeting. Among them, lentiviral vectors are currently widely used, 3 as they can insert their genome into the host genome, leading to stable gene expression. Nevertheless, this property cannot be considered safe, as the insertion can activate oncogenes or promote gene silencing, resulting in severe adverse events. 4 In contrast, episomal adenoviruses do not require the insertion of viral DNA into the host genome, and thus do not pose the risk of mutagenesis. [5] [6] [7] In vitro, the binding of species C human adenoviruses (HAdV) to the cell surface is initiated by a primary high-affinity interaction between the capsid fiber knob of the virus 8 and a 46-kDa cell-surface glycoprotein receptor, hCAR (human coxsackie and adenovirus receptor). A second interaction between the penton base RGD motif of the virus and cellular integrin coreceptors leads to HAdV clathrin-coated pit endocytosis of HAdV. 9 Heparan sulfate proteoglycans have also been identified as receptors for species C HAdV in vitro 10 and in vivo. In vivo, the context is more complex, and the intravenous injection of HAdV vectors leads to transgene expression in the liver. 11 Attempts to modify this in vivo HAdV liver tropism by suppressing CAR and/or integrin interactions have proven to be unsuccessful. [12] [13] [14] Certain blood coagulation factors (FIX, FX) and the complement component 4 (C4)-binding protein have major roles in the uptake of intravenously injected HAdV by hepatocytes, although scavenger receptors seem to be involved in its uptake by Kupffer cells. These blood factors form a bridge linking HAdV to hepatocellular heparan sulfate proteoglycans and to the low-density lipoprotein receptor-related protein. 15, 16 Recent studies have highlighted the role of a high-affinity interaction of FX with the HAdV-5 hexon in liver gene transfer. [17] [18] [19] [20] Adenoviral entry into specific cell types can be achieved by genetic retargeting strategies involving the engineering of the viral fiber protein, which participates in the binding of the virus to target cells. 21 We have previously demonstrated that one of the advantages of the restricted tropism of adenoviral vectors is that infection is limited to cells that are naturally permissive to the most frequently encountered human adenoviral species, and vector dissemination is thus avoided. 9 In mice, this results in a great reduction in humoral and innate cytokine-mediated immune responses following the intravenous administration of adenoviral vectors in mice. 22, 23 Whereas preclinical studies using oncolytic adenoviral vectors have shown promising results, clinical trials to date have been disappointing. 24 Their limitations have been linked to inefficient tumor-cell transduction and the lack of penetration of viral vectors into a solid tumor mass. The correlation between the expression of the primary receptor for adenoviruses, hCAR and viral infection is still controversial, 25, 26 but it appears that a significant reason for the disappointing outcome with HAdV-5-based vectors could be the low expression of hCAR on glioblastoma cells, leading to poor infection efficiency. [27] [28] [29] Engineering new vectors capable of targeting brain tumor cells is thus crucial. 28, [30] [31] [32] [33] Functional targeting by modified adenoviral vectors depends on at least two criteria: the density of the targeted receptors and their ability to be internalized by cells. 23, 34 We hypothesized that the type 2A SRIF (somatotropin release-inhibiting factor) receptor (sstr2A) could be a promising cell-surface protein target in glioma cells. Indeed, (i) sstr2A is expressed at high densities on the surface of human glioblastoma cells but not on normal glial cells, 35 and (ii) sstr2A is internalized by human glioma cells mainly through caveolin-positive uncoated vesicles, and to a lesser extent, through clathrin-coated vesicles, 36,37 the two main pathways described for adenoviral uptake. 9, 38 The natural ligand of the sst2A receptor is the neuropeptide SRIF also known as somatostatin. SRIF is expressed both in the periphery and in the CNS and has multiple functions: among others, it regulates endocrine and exocrine secretion, exhibits antiproliferative properties and acts as a neuromodulator. 39 Five distinct receptors subtypes, sstr1 to 5, mediates the actions of somatostatin. 40, 41 Interestingly, gliomas differ from non-malignant glial cells by their overexpression of the type 2 SRIF receptor (sstr2), and especially of the splice variant sstr2A. 35, 42 The fact that SRIF is only 14 amino acids long and can easily be inserted into the viral HI loop makes this receptor-ligand system an ideal target for the infection of glioma cells by adenoviral vectors.
In the present study, we therefore generated a HAdV-5-SRIF vector containing the full-length SRIF sequence within the HI loop of its fiber protein, to deliver genes to glioma cells. Using this new vector, we provide proof of concept for sstr2A targeting by HAdV-5-SRIF (i) in vitro, in several cell lines, and (ii) ex vivo, using highgrade human primary glioblastoma cells. Taken together, our results suggest that targeting adenoviral vectors to sstr2A could provide a new strategy for the efficient transfer of genes to human glioblastoma cells.
RESULTS

Molecular engineering and characterization of an adenoviral
vector containing the SRIF sequence in its fiber protein (HAdV-5-SRIF) A peptide containing the SRIF sequence surrounded by aminoacid spacers (serine, glycine) to enhance peptide flexibility (SGAGCKNFFWKTFTSCG) was engineered in our laboratory. The modified viral genome containing the SRIF sequence in the HI loop of the viral fiber gene was obtained after homologous recombination in E. coli as previously described. 43 ExPASY software allowed us to predict that the external position of the ligand in the HI loop of the viral protein would lead to enhanced receptor-ligand recognition (Figure 1a , yellow). Genetically modified adenovirus was produced at a high titer (B10 12 physical particles (PP) per ml) as previously described by our group. 22 Immunoblot analyses confirmed the presence of the modified fiber protein in its monomeric (Figure 1b , left panel) and trimeric forms (Figure 1b, right panel ). An increase in the apparent molecular mass of the viral fiber protein containing the SRIF sequence (63.6 kDa) was observed ( Figure 1b , left panel; compare lanes 1 and 2). Under non-denaturing conditions, we also detected a band with an apparent molecular mass of 617 kDa for HAdV-5-SRIF (Figure 1b , right panel, grey symbol). This band could correspond to the previously characterized association of the fiber protein with the penton base protein. 44 Additionally, the particle structure of the SRIF-carrying adenoviral vector was checked by electron microscopy and showed no conformational alteration when compared with the normal HAdV-5 vectors (Figures 1c and  d) . Taken together, these results indicate that SRIF-fiber proteins are correctly assembled in to the HAdV-5 viral particle. To assess the presence of the SRIF sequence in our modified vector, viral DNA was extracted from batches of viral particles, and PCR with specific primers flanking the SRIF sequence used to confirm the chimeric nature of the viruses. The HAdV-5 fiber amplification product was detected at 641 base pairs, whereas the chimeric fiber amplification product was detected at 692 base pairs (Figure 1e ).
Characterization of CAR, integrins and somatostatin receptors in cell lines and human glioblastoma primary cultures To determine the involvement of sstr2A and CAR/integrins in the transduction of HAdV-5-SRIF, we analyzed the expression level of SRIF receptors by RT-PCR and the level of CAR, human a v b 3 and/or mouse a v integrins by flow cytometry. Sstr2A was expressed in N1E115, SH-SY5Y and T98 cell lines and primary glioblastoma cultures; whereas it was absent from CHO and CHO-CAR (CARexpressing CHO) cell lines (Table 1a ). CAR and/or integrins were expressed at different levels in CHO-CAR, N1E115, SH-SY5Y and T98 cells.
HAdV-5-SRIF mediates gene delivery in cell lines expressing sstr2A The cell lines listed above were infected with increasing titers of HAdV-5-SRIF or HAdV-5 viral particles. b-galactosidase (b-gal) activity was quantified by flow cytometry 24 h post infection. Cells were infected by HAdV-5-SRIF in a dose-dependent manner: the parental HAdV-5 vector, which also infected cells owing to the presence of CAR and integrins at the cell surface (Table 1b) , nevertheless drove lower levels of reporter gene activity (Figures  2a-d) . Even at the lowest concentration used (0.5 Â 10 3 PP per cell), HAdV-5-SRIF was capable of inducing a 56-fold enhancement of b-gal activity in SH-SY5Y cells (Figure 2c , Po0.01). In contrast, HAdV-5-SRIF was not able to deliver genes to adenovirus-resistant CHO (Chinese Hamster Ovary cells) cells 22 that did not express sstr2A ( Figure 3d , Table 1a ).
The targeting of sstr2A was further demonstrated using several independent tests. The first consisted of blocking sstr2A using a specific agonist, octreotide. 45, 46 This SRIF analog binds mainly to sstr2A and with less affinity to sstr3/5. Residual binding to sstr1/4 has also been described. 40 The effect of octreotide on a human glioblastoma cell line (T98), that express only subtypes 1 and 2 (Table 1a) clearly demonstrates the specificity of sstr2A targeting. Pretreatment with this agonist reduced the sensitivity of T98 cells to the modified virus in a dose-dependent manner (Figure 3a , Po0.01 to Po0.001). In the presence of 25 nmol of octreotide, the inhibition of HAdV-5-SRIF infectivity increased by 80% (Figure 3b) . Our results also demonstrate that transduction is blocked at the level of cell-surface binding and not at a post-entry step. Indeed, Figure 3c shows that octreotide inhibits HAdV-5-SRIF binding to T98 cells in a dose-dependent manner, although it has no noticeable effect on HAdV-5 binding.
In a parallel approach, we induced the transient and exogenous expression of sstr2A in an adenovirus-resistant CHO cells that do not express CAR (CHO) (Figure 3d ). 47 Our results show that HAdV-5-SRIF triggers a five-fold enhancement of b-gal activity in these cells (Figure 3d , Po0.01). We further examined the role of CAR and/or integrins in the transduction of HAdV-5-SRIF. As expected, HAdV-5-SRIF, in which CAR/integrin-binding sequences were conserved, was still able to infect CHO-CAR cells (Figure 4a ). In a second set of experiments, we performed blocking analyses using non-labeled HAdV-5 to infect CHO-CAR and T98 cells, as previously carried out by our group. 22 Our results confirm that HAdV-5 is able to compete with HAdV-5-SRIF for binding to both CHO-CAR and T98 cells (Figures 4b and c) . Interestingly, this ability is stronger in CHO-CAR cells, which do not express sstr2A, than in T98 cells. These results suggest that when expressing both CAR/integrins and sstr2A (Table 1) , HAdV-5-SRIF also uses sstr2A for infection (Figure 4c ).
Taken together, these independent controls strengthen the notion that HAdV-5-SRIF is capable of delivering genes in vitro through an sstr2A-dependent pathway and driving their expression in glioblastoma cells.
Internalization of HAdV-5-SRIF through sstr2A We then wondered if HAdV-5-SRIF entry and infection is contingent upon sstr2A internalization. Two cell lines were selected, one expressing sstr2A ectopically (CHO-sstr2A) and one expressing sstr2A endogenously (SH-SY5Y). CHO cells were transiently transfected with EGFP-tagged sstr2A complementary DNA (cDNA), followed by infection with HAdV-5 or HAdV-5-SRIF (1 Â 10 3 or 5 Â 10 3 PP per cell), and receptor internalization was tracked by confocal microscopy. HAdV HAdV-5 infection (Figure 3d ), and our previously published results. 22 Moreover, even after 60 min, most HAdV-5 particles were still localized at the cell membrane ( Figure 5b , upper panels).
These results were confirmed in the human neuroblastoma SH-SY5Y ( Figure 6 ) and human glioblastoma T98 cell lines (Supplementary figure S1), which endogenously express sstr2A. Cells were treated with octreotide (50 nM) or with viral particles (HAdV-5 or HAdV-SRIF, 10 11 PP ml À 1 ) and incubated at 37 1C for 15-60 min. Sstr2A was then immunolabeled and its uptake followed by confocal microscopy. The parental vector, HAdV-5, was internalized by cells to a lesser extent than HAdV-5-SRIF, and could not induce sstr2A uptake ( 
HAdV5-SRIF-mediated transduction of primary human glioblastoma cells ex vitro
Having highlighted the potential of the HAdV-5-SRIF vector to infect several cell lines, we wondered if it was capable of infecting primary cultured glioblastoma cells that endogenously express sstr2A. Primary cultures were obtained from a human glioblastoma tissue sample and the presence of sstr2A mRNA was confirmed as shown in Table 1a . These primary cultures were then infected with increasing doses of either HAdV-5-SRIF or the parental vector HAdV-5. Our results showed that the HAdV-5-SRIF-mediated reporter-gene expression in primary human glioblastoma cells, which endogenously express sstr2A mRNA, was up to 75-fold greater than with HAdV-5 (Figures 8a and b, n ¼ 5, Po0.01).
DISCUSSION
Virotherapy for cancer has opened new perspectives in the treatment of tumors such as gliomas. 48, 49 Among the available viral vectors, adenovectors are used in several clinical trials because they are non-integrating viruses, and oncolytic vectors can be used to mediate tumor cell death. However, one of the keys to the success of virotherapy is the specific targeting of tumor cells, limitations in which could explain in part why clinical trials using oncolytic adenoviral vectors have been disappointing. 24 Technologies being developed to improve cell targeting include pseudotyping, retargeting to specific cell-surface receptors and coating with reactive polymers. [50] [51] [52] [53] In addition, the use of cell-type-specific promoters, and more recently, the possibility of introducing miRNA target sequences to prevent expression in undesired cells 54, 55 further improve this specificity. However, few vectors have as yet been designed to selectively target glioma cells. 24 In the present work we demonstrate that the type 2A SRIF receptor is a relevant target for the delivery of genes into human glioblastoma cells, using adenoviral vectors with modified fiber genes. We generated a new chimeric adenoviral vector by the insertion of the full-length SRIF peptide into the HI loop of the adenoviral fiber knob to target sstr2A. No mutation in either the CAR-or in the integrin-binding sites 56, 57 was introduced in this construction.
The full-length SRIF peptide was selected because its biological properties, including receptor internalization and subsequent events, could depend on the presence of the complete sequence. SRIF receptors belong to the family of G-protein-coupled receptors. Molecules that bind to G-protein-coupled receptors can induce distinct conformational changes depending on the nature of the interaction, and it is possible that the natural conformation of the ligand is required for these conformational changes in the receptor. Indeed, recent data have demonstrated that sstr2A agonists do not necessarily mimic all the effects induced by the native hormone. Notably, some of them clearly show altered sstr2A internalization. 58 Here we provide evidence that the modified virus containing the SRIF peptide infects cells expressing endogenous (Figure 2 ) or transfected sstr2A (Figure 3 ). HAdV-5-SRIF efficiently infects cells expressing endogenous sstr2A in a dose-dependent manner, whereas infection with the parental HAdV-5 vector is poor. These results complete and extend an elegant study recently published by Leja et al., 33 in which the authors developed oncolytic adenoviral vectors with short SRIF motifs to transfer genes into neuroendocrine tumors. Our data demonstrate that full-length SRIF in the context of an adenoviral vector is capable of targeting sstr2A, and that it confers a strong benefit on sstr2A-positive cells enhancing gene expression by up to 65-fold when compared to native HAdV-5 ( Figure 2) .
To further reinforce our data, we verified the intracellular trafficking of sstr2A and viral particles in cells expressing sstr2A either endogenously or ectopically. CHO cells overexpressing sstr2A were infected with the vectors and the internalization process of receptors and viral particles analyzed ( Figure 5 ). HAdV-5-SRIF infects only CHO cells expressing GFP-tagged sstr2A, and is subsequently internalized by inducing receptor uptake. Neither infection (Figure 3d ) nor sstr2A internalization (Figure 5a ) occurs with the HAdV-5 parental vector. These results were further confirmed in SH-SY5Y cells (Figure 6 ), which endogenously express sstr2A (Table 1) . Moreover, these intracellular trafficking studies show that, contrary to octreotide, 45 HAdV-5-SRIF does not induce the accumulation of sstr2A in 'trans-Golgi-like' structures. Sstr2A, a cell surface target in glioma cells K Lé colle et al Indeed, once internalized, adenoviral vectors are rapidly released from early endosomes. 59 Our results also show that this vector is still capable of using CAR to infect cells in which the latter is expressed (Table 1b) . Nevertheless, competition assays (Figures 4b  and c) show that HAdV-5-SRIF is more efficient at infecting cells that express high levels of sstr2A and low levels of CAR and/or integrins, which is a definite advantage when it comes to glioblastoma cells.
The results we obtained using cell lines also hold true for primary cultures of glioblastoma. Indeed, we show that HAdV-5-SRIF is able to drive gene expression with an enhancement of up to 75-fold in comparison to HAdV-5. This property allows the use of a low amount of vector (100 PP per cell) to transduce primary cells cultured from an explant of a high-grade human glioblastoma ex vivo (Figure 8 ).
To summarize, HAdV-5-SRIF containing the full-length SRIF sequence in its cell-surface-binding protein has permitted us to obtain proof of concept for the idea that SRIF receptors could represent a gateway for the delivery of toxic genes into primary glioma cells that overexpress these receptors.
Before the transfer of such vectors to clinical trials, however, many other considerations must be taken into account. First of all, neither the CAR-nor the integrin-binding site of the HAdV-5-SRIF vector used in this study was modified. This is a problem, considering that cells in a tumoral environment can express CAR and/or integrins. Although sstr2A is overexpressed in glioma cells and absent in normal glial cells, we cannot exclude the possibility of an undesired infection of non-tumoral cells such as neuronal cells surrounding the tumors. Secondly, the neuropeptide SRIF has important physiological effects, mostly inhibitory, that are mediated by its receptors. 39 A major issue with SRIF receptor targeting is thus receptor desensitization in neuronal cells, and type 2 SRIF receptors are very sensitive to downregulation not only in vitro 60 but also in vivo. 45, 61 In addition, temporal lobe epileptic seizures, which lead to the release of large amounts of endogenous SRIF, result in the sustained loss of surface sstr2A expression in the dentate gyrus of both rat and human brains. 62, 63 This could in turn contribute to epileptogenesis and seizure susceptibility. Targeting SRIF receptors in non-tumoral cells could potentially decrease the density of cell-surface receptors and disrupt the normal physiological functions of the neuropeptide.
Finally, even if adenoviral vectors are promising vehicles for gene therapy strategies, the immune responses triggered by viral vectors need to be reduced to achieve efficient gene transfer. The systemic administration of high titers of viral vectors is Sstr2A, a cell surface target in glioma cells K Lé colle et al associated with innate and adaptive immune responses against both viral particles and gene products, leading to the decreased efficiency of gene transfer or elimination of transduced cells over time. Several approaches have been proposed to bypass immune responses after adenoviral gene transfer, 64 notably modifications of capsid structure. In this context, we have recently demonstrated that genetic modifications of our particular fiber protein strongly reduce the humoral and cellular immune responses associated with unmodified adenoviral vectors. 23 Moreover, in the case of gliomas, the direct intracranial injection of viral vectors into the tumor is required. This route not only eliminates the problem of having to deliver molecules into the brain across the blood-brain barrier, it also reduces viral toxicity, as demonstrated by a clinical trial involving 36 patients treated with HAdV-HSV-tk vectors by local injection, with no adverse effects. 65 Such observations clearly highlight the fact that stringent specificity is a prerequisite for the engineering of vectors that can be transferred to the clinic without any adverse events. Many options to increase specificity are now available, such as the association of the oncolytic properties of adenoviruses with cell-surface targeting, cell-specific promoters and more recently, the possibility of introducing miRNA target sequences to prevent expression in undesired cells. 54, 55 All these modifications will be included in a second generation of HAdV-5-SRIF-derived vectors.
To conclude, our data demonstrate that (i) HAdV-5-SRIF uptake into cells is mediated by sstr2A, (ii) our vector drives high gene expression levels in cells expressing endogenous sstr2A, with up to 75-fold enhancement in human primary glioblastomas cells, (iii) low doses of HAdV-5-SRIF are sufficient to efficiently infect primary high-grade human glioblastoma cells. Our results, taken as a whole, provide proof of concept that the targeting of sstr2A receptors is of great interest for the delivery of toxic genes to human glioblastomas.
MATERIALS AND METHODS
Adenoviral engineering
We have previously constructed a recombinant HAdV-5 vector with the substitution of the E1 region by a b-gal reporter gene under the control of the CMV immediate early promoter. 43 The full-length SRIF sequence (SGAGCKNFFWKTFTSCG) with spacers (bold letters) was inserted into the viral HI loop in a shuttle vector containing the wild-type HAdV fiber gene. The corresponding viral genome was obtained by homologous recombination in the E. coli BJ5183 strain as previously carried out by our group. 22, 43 The putative position of the SRIF peptide in the HI loop was evaluated using ExPASY software (Swiss Institut of Bioinformatics).
The HAdV-5-SRIF and HAdV-5 vectors were amplified and purified following conventional protocols. 38 As HAdV-5-SRIF displays less tropism for epithelial cells than HAdV-5, it was not possible to compare the infectious titers of the modified and native vectors by conventional plaque assays on HEK-293 cell monolayers. Stocks of purified vectors were titrated by optical measurement of the viral DNA concentration at 260 nm, and the vector titer expressed as the number of PP of the virus per ml. All viral production was performed in appropriate areas in compliance with institutional protocols for genetically modified organism manipulation, as recommended by the 'Comité Scientifique du Haut Conseil des Biotechnologies' (identification number 5258).
Electron microscopy
For the negative staining of virus particles, carbon-coated grids (Euromedex, Souffelweyersheim, France) were floated on a drop of viral suspension (5 Â 10 8 PP of HAdV-5 or HAdV-5-SRIF) for 10 min. Excess fluid was removed using filter paper. The grids were then floated on a drop of staining solution (2% uranyl acetate) for 1 min. After air drying, the grids were observed under a transmission electron microscope (Zeiss EM902, Carl Zeiss S.A.S, Le Pecq, France).
Cell culture
Cell-line cultures. CHO (Chinese Hamster Ovary), N1E115 (mouse neuroblastoma), SH-SY5Y (human neuroblastoma) and T98 (human Sstr2A, a cell surface target in glioma cells K Lé colle et al glioblastoma) cells were cultivated in Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal bovine serum, non-essential amino acids (1%), penicillin/streptomycin (1%) and L-glutamine (1%). Cells were maintained in a humidified incubator with 5% CO 2 . All cell lines were passaged twice a week.
Primary cultures. A human glioblastoma specimen was obtained from the Neurosurgery Clinic of the University Hospital of Lille. The tumor was classified and graded by a neuropathologist according to the World Health Organization classification. 66 Written informed consent was previously obtained from the patient and/or family members. Permission to utilize human brain tissue was obtained from the French agency for biomedical research (Agence de la Biomé decine, Saint-Denis la Plaine, France). Immediately after surgery, the glioblastoma sample was disinfected with Betadine solution and rinsed several times in phosphate-buffered saline (PBS). The tissue sample was then dissociated by successive passages through 80 and 20 mm nylon meshes (Buisin, Vaux-en-Bugey, France) to obtain a single-cell suspension. Dissociated cells were transferred to a 75-cm 2 culture flask (Becton Dickinson, Meulan, France) and cultured in DMEM-F12 supplemented with 10% fetal bovine serum, 1% L-glutamine and 2% antibiotics (penicillin/streptomycin) under a humid atmosphere of 5% CO 2 -95% air at 37 1C. After a few weeks in culture, cells were trypsinized, counted and plated in six-well poly-D-lysine-and laminincoated Labtek plates (Becton Dickinson Bioscience Europe, Erembodegem, Belgium) at 10 000 cells per well. Cells derived from the glioblastoma biopsy exhibited an elongated shape with long and thin processes. From 3 weeks in culture on, cellular spheres sprouted from very dense areas of the cellular layer. At 1 month in vitro, cultures were composed of a dense monolayer of elongated cells, with cell buds sprouting from the monolayer and numerous floating spheres. This stands in contrast to cells derived from non-tumoral adult cerebral cortex biopsies cultured following the same procedure, which we have characterized elsewhere. 67 These nontumoral primary cultures were composed of a monolayer of flat polygonal astrocytes that exhibit a low rate of proliferation, as confluence was only reached after 2-3 months in vitro. In addition, unlike tumor-derived cultures, adult primary astrocytes could not be readily passaged and amplified over time, and never gave rise to floating cellular spheres.
HAdV infection
Adherent cells were seeded in six-well cell culture plates at a density of 10 6 cells per well, incubated at 37 1C in serum-free medium, and then infected with 0.5, 1, 2 or 5 Â 10 3 PP per cell of HAdV-5 or HAdV-5-SRIF for 2 h at 37 1C. Medium containing 4% fetal bovine serum was added for a further 24-h post-infection period at 37 1C. Viral infection efficiency was determined by measuring b-gal activity. For this purpose, cells were infected with viruses in serum-free medium. After infection, cells were washed and cytometric analyses were performed after reaction with fluorescein DI-(b-D-galactopyranoside) (Sigma-Aldrich, Lyon, France) at a final concentration of 0.1 mg ml À 1 for 10 min at 37 1C. For primary cultures, viruses were added at various concentrations (0.5-5 Â 10 3 PP per cell) for 2 h at 37 1C in a minimal volume (300 ml) of the appropriate medium as described above, before adding 300 ml of the same medium for a further 24-h post-infection period. b-gal activity was estimated using a colorimetric assay. Briefly, cells were fixed with 0.25% glutaraldehyde and exposed to a solution of 1 mg ml À 1 X-gal (SigmaAldrich), 2 mM MgCl 2 , 5 mM K 3 Fe(CN) 6 figure (a, b and c) , an xz representation is shown. The specific location of sstr2A is also quantified across the cells (profile). 
Competition assays
Binding competition assays. T98 cells (10 6 per aliquot) were suspended in PBS with 1% BSA and incubated for 1 h at 4 1C with octreotide (0 to 25 nmol, Sigma-Aldrich). After rinsing, cells were incubated for 1 h at 4 1C in the presence of 10 10 PP of HAdV-5-SRIF or HAdV-5 labeled with FAM (carboxyfluorescein succinimidyl ester; Invitrogen), and viral binding was quantified by flow cytometry.
Transduction competition assays. T98 cells were plated in six-well cell culture plates at a density of 0.8 Â 10 6 cells per well. After 24 h, increasing amounts of the sstr2A receptor agonist octreotide diluted in serum-free medium were added for 60 min at 37 1C, before infection with 2 Â 10 3 PP per cell of HAdV-5 or HAdV-5-SRIF. Medium containing 4% fetal bovine serum was added for a further post-infection period of 24 h at 37 1C. Cells were then collected, and b-gal activity determined as described above. The percentage of inhibition was determined relative to the level of viral infection obtained in the absence of octreotide.
Intracellular trafficking studies
Sstr2A was overexpressed in CHO cells using GFP-tagged sstr2A cDNA as described above. Cells were then infected with 1 Â 10 3 or 5 Â 10 3 PP per cell of HAdV-5 or HAdV-5-SRIF diluted in serum-free medium and incubated for 20 min at 37 1C. Control cells were incubated with 50 nM of octreotide to induce sstr2A uptake. Cells were rinsed and processed for confocal microscopy as previously described.
38
Sstr2A was overexpressed in CHO cells using untagged sstr2A cDNA, as described above. Fluorescent labeling of vector particles with FAM was performed as previously described. 47 Cells were incubated at 4 1C for 1 h with 10 11 PP ml À 1 of FAM-labeled HAdV-5-SRIF in serum-free medium, and rinsed with PBS containing 1% BSA. For uptake assays, cells and vector were transferred to 37 1C for 5-30 min Cells were rinsed and processed as previously described. 38 SH-SY5Y cells were seeded onto Labtek chambers. Octreotide (50 nM), FAM-labeled HAdV-5-SRIF or FAM-labeled HAdV-5 (10 11 PP ml À 1 ) was then added to the cells for 0-60 min at 37 1C. Cells were fixed in 4% PFA for 20 min at room temperature, and rinsed twice with 50 mM of NH 4 Cl. Cells were then permeabilized with Triton X-100 (0.2%, 10 min at room temperature) and rinsed twice with 50 mM of NH 4 Cl. Cells were then incubated with a rat monoclonal primary antibody to the sstr2A receptor (Epitomics, Burlingame, CA, USA; 1:100) at 4 1C overnight, and labeling revealed the following day using a secondary Alexa Fluor 568-labeled goat anti-rat IgG (Invitrogen; 1:400) for 45 min at room temperature. Cells were mounted with Vectashield medium containing DAPI (Vector, Burlingame, CA, USA).
SH-SY5Y or T98 cells were seeded onto Labtek chambers. FAM-labeled HAdV-5-SRIF or HAdV-5 (10 11 PP ml À 1 ) was then added to the cells for 30 min at 37 1C. Cells were fixed in 4% PFA for 20 min at room temperature, and rinsed twice with 50 mM of NH 4 Cl. Cells were then permeabilized with Triton X-100 (0.2%, 10 min at room temperature) and rinsed twice with 50 mM of NH 4 Cl. Cells were then incubated with a mouse monoclonal primary antibody against b-tubulin (Sigma-Aldrich; 1:200) at 4 1C overnight and labeling revealed the following day using a secondary Alexa Fluor 568-labeled goat anti-mouse IgG (Invitrogen; 1:400) for 45 min at room temperature. Cells were mounted with Vectashield medium containing DAPI (Vector).
All intracellular trafficking studies were carried out using a TCS SP Leica (Lasertechnik GmbH, Jena, Germany) microscope.
Immunoblot analysis
HAdV-5-SRIF or HAdV-5 (10 11 PP) was diluted in sample buffer with or without b-mercaptoethanol, and proteins separated by PAGE on a 4-8% gradient gel under denaturing conditions or on a 4-16% gradient native gel (Invitrogen) under non-denaturing conditions. Migration was carried out overnight and proteins were transferred onto a nitrocellulose membrane. After saturation in fat-free milk, the blots were incubated in 10 ml of a solution of primary monoclonal antibody against adenoviral fiber (1:1200, Interchim, Montluc¸on, France, clone 4D2) as previously Sstr2A, a cell surface target in glioma cells K Lé colle et al described. 22, 68 Blots were then incubated in 40 ml of the appropriate HRP-conjugated secondary antibody (1:10 000), washed and incubated in ECL reagent (GE Healthcare Europe, GmbH, Saclay, France).
PCR/RT-PCR analyses
PCR verification of fiber DNA sequence from viral particles. After digestion for 60 min with 0.9 M of proteinase K, viral DNA was extracted from 10 11 PP of HAdV-5 or HAdV-5-SRIF using the Nucleospin tissue kit (Macherey-Nagel, Hoerdt, France), as recommended by the manufacturer. Fiber knob DNA was amplified by PCR using 1 mM of the following specific oligonucleotides: 5 0 -GTGGGAGTCAAGTACTAGCTAC-3 0 and 5 0 -GGCAGGTTGAATACTAGGGTT C-3 0 , 10 ml of viral DNA, 200 nM of dNTPs and 1 unit of DNA polymerase (DyNAzyme EXT, Thermo Scientific Finnzymes, Vantaa, Finland). Amplified DNA (500 mg) was electrophoresed on a 4% agarose gel with 1 mg ml À 1 of ethidium bromide.
RT-PCR detection of sstr2A mRNA. RT-PCR of sstr2A mRNA was carried out using total RNA. Cells were lysed and total RNAs were extracted with the Nucleospin RNA II kit (Macherey-Nagel), as recommended 0.5x10 
Statistical analysis
Data are presented as the means ± s.e.m. of experiments performed in duplicate, and are representative of results obtained from three or four independent experiments that all yielded similar results. Statistical analyses were performed for three independent experiments using the Mann-Whitney test. The threshold for significance was set at Po0.05.
